{"title":"Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease.","authors":"Ayaka Hayashi, Hiroto Ishihara, Mayuko Kawabe, Kazuhiko Kato, Akio Nakashima, Izumi Yamamoto, Teppei Sakano, Hiroe Kobashi, Makoto Morita, Takashi Yokoo, Mitsuyoshi Urashima","doi":"10.3389/fmed.2025.1530804","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Programed death-ligand 1 (PD-L1) is overexpressed on renal tubular and vascular epithelial cells in inflammatory kidney diseases as well as on aged kidney podocytes, contributing to chronic kidney disease (CKD) progression. The association of serum soluble programed death-ligand 1 (sPD-L1) levels and chronic kidney disease (CKD) progression is unknown.</p><p><strong>Methods: </strong>To compare serum sPD-L1 levels among healthy individuals and patients with various CKD stages, including those undergoing dialysis, a secondary analysis was performed using clinical data and residual serum samples from four distinct cohorts, each prospectively collected for different research purposes: The Vaccine Cohort (2021-2022), the Cancer Cohort (2010-2018), the Dialysis Initiation Cohort (2023-2024), and the Dialysis Maintenance Cohort (2011-2015) included patients on stable maintenance dialysis.</p><p><strong>Results: </strong>The study analyzed serum sPD-L1 levels in 2,829 participants (mean age, 54.2 years; male, 54.2%) across the four cohorts. In the Vaccine and Cancer cohorts, sPD-L1 levels increased significantly with age (<i>P</i> < 0.001) and male sex (<i>P</i> < 0.001). In the Vaccine Cohort, elevated median sPD-L1 levels (pg/mL) were significantly associated with CKD stage progression (<i>P</i> < 0.001), showing exponentially higher levels with CKD progression. A similar association was observed and validated in the Cancer Cohort (<i>P</i> < 0.001). In the Dialysis Initiation Cohort (<i>n</i> = 15), sPD-L1 levels significantly increased three months after dialysis initiation compared to pre-dialysis levels (<i>P</i> = 0.03). In the Dialysis Maintenance Cohort, sPD-L1 levels increased with longer dialysis duration (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>Serum sPD-L1 levels might increase with CKD stage progression, dialysis initiation and longer dialysis duration. Further clinical investigation is required to confirm these results.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1530804"},"PeriodicalIF":3.1000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826805/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1530804","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Programed death-ligand 1 (PD-L1) is overexpressed on renal tubular and vascular epithelial cells in inflammatory kidney diseases as well as on aged kidney podocytes, contributing to chronic kidney disease (CKD) progression. The association of serum soluble programed death-ligand 1 (sPD-L1) levels and chronic kidney disease (CKD) progression is unknown.
Methods: To compare serum sPD-L1 levels among healthy individuals and patients with various CKD stages, including those undergoing dialysis, a secondary analysis was performed using clinical data and residual serum samples from four distinct cohorts, each prospectively collected for different research purposes: The Vaccine Cohort (2021-2022), the Cancer Cohort (2010-2018), the Dialysis Initiation Cohort (2023-2024), and the Dialysis Maintenance Cohort (2011-2015) included patients on stable maintenance dialysis.
Results: The study analyzed serum sPD-L1 levels in 2,829 participants (mean age, 54.2 years; male, 54.2%) across the four cohorts. In the Vaccine and Cancer cohorts, sPD-L1 levels increased significantly with age (P < 0.001) and male sex (P < 0.001). In the Vaccine Cohort, elevated median sPD-L1 levels (pg/mL) were significantly associated with CKD stage progression (P < 0.001), showing exponentially higher levels with CKD progression. A similar association was observed and validated in the Cancer Cohort (P < 0.001). In the Dialysis Initiation Cohort (n = 15), sPD-L1 levels significantly increased three months after dialysis initiation compared to pre-dialysis levels (P = 0.03). In the Dialysis Maintenance Cohort, sPD-L1 levels increased with longer dialysis duration (P < 0.001).
Conclusion: Serum sPD-L1 levels might increase with CKD stage progression, dialysis initiation and longer dialysis duration. Further clinical investigation is required to confirm these results.
期刊介绍：
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
